Skip to main content

Remote Job Finders (RJF)

Lilly, FDA retatrutide biologic dispute comes to a head as submission nears

A legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicine for approval.

Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees

Seven months after launching with $16 million in seed financing, Jennifer Doudna’s Aurora Therapeutics is pivoting away from its lead indication, phenylketonuria, owing to growing competition in the field.
Scroll to top